S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
Flee to Healthcare Stocks if Recession Rears its Head?
BREAKING: Tiny biotech successfully treats blindness (Ad)
3 Tasty Dividend Stocks With Value and Above-Average Yields
3 ETFs for the Conservative Investor to Buy and Hold
BREAKING: Tiny biotech successfully treats blindness (Ad)
Stock market today: World shares track Wall Street's slump after Fed says rates may stay high in '24
5 NYSE-Listed Emerging Market Stocks For Income Investors
BREAKING: Tiny biotech successfully treats blindness (Ad)
Disney Denies Rumors of TV Sale, After Stock Jumps on News
Are These Consumer Staples Too Cheap for Investors To Ignore?
S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
Flee to Healthcare Stocks if Recession Rears its Head?
BREAKING: Tiny biotech successfully treats blindness (Ad)
3 Tasty Dividend Stocks With Value and Above-Average Yields
3 ETFs for the Conservative Investor to Buy and Hold
BREAKING: Tiny biotech successfully treats blindness (Ad)
Stock market today: World shares track Wall Street's slump after Fed says rates may stay high in '24
5 NYSE-Listed Emerging Market Stocks For Income Investors
BREAKING: Tiny biotech successfully treats blindness (Ad)
Disney Denies Rumors of TV Sale, After Stock Jumps on News
Are These Consumer Staples Too Cheap for Investors To Ignore?
S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
Flee to Healthcare Stocks if Recession Rears its Head?
BREAKING: Tiny biotech successfully treats blindness (Ad)
3 Tasty Dividend Stocks With Value and Above-Average Yields
3 ETFs for the Conservative Investor to Buy and Hold
BREAKING: Tiny biotech successfully treats blindness (Ad)
Stock market today: World shares track Wall Street's slump after Fed says rates may stay high in '24
5 NYSE-Listed Emerging Market Stocks For Income Investors
BREAKING: Tiny biotech successfully treats blindness (Ad)
Disney Denies Rumors of TV Sale, After Stock Jumps on News
Are These Consumer Staples Too Cheap for Investors To Ignore?
S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
Flee to Healthcare Stocks if Recession Rears its Head?
BREAKING: Tiny biotech successfully treats blindness (Ad)
3 Tasty Dividend Stocks With Value and Above-Average Yields
3 ETFs for the Conservative Investor to Buy and Hold
BREAKING: Tiny biotech successfully treats blindness (Ad)
Stock market today: World shares track Wall Street's slump after Fed says rates may stay high in '24
5 NYSE-Listed Emerging Market Stocks For Income Investors
BREAKING: Tiny biotech successfully treats blindness (Ad)
Disney Denies Rumors of TV Sale, After Stock Jumps on News
Are These Consumer Staples Too Cheap for Investors To Ignore?
NASDAQ:VIRI

Virios Therapeutics (VIRI) Stock Forecast, Price & News

$1.02
-0.05 (-4.67%)
(As of 09/20/2023 ET)
Compare
Today's Range
$0.96
$1.07
50-Day Range
$0.86
$2.42
52-Week Range
$0.22
$2.42
Volume
217,500 shs
Average Volume
271,886 shs
Market Capitalization
$19.64 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Virios Therapeutics MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
2.42% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.10mentions of Virios Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$51,186 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.34) to ($0.33) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.02 out of 5 stars

Medical Sector

602nd out of 962 stocks

Pharmaceutical Preparations Industry

274th out of 448 stocks


VIRI stock logo

About Virios Therapeutics (NASDAQ:VIRI) Stock

Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Innovative Med Concepts, LLC and changed its name to Virios Therapeutics, Inc. in July 2020. Virios Therapeutics, Inc. was founded in 2012 and is headquartered in Alpharetta, Georgia.

VIRI Price History

VIRI Stock News Headlines

Virios Therapeutics, Inc. (NASDAQ:VIRI) Short Interest Update
Buy This Stock for AI Tidal Wave (not NVDA)
The internet boom made more millionaires than any tech  - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.
Virios Therapeutics (NASDAQ:VIRI) Shares Down 3.2%
BREAKING: The truth about war with China
Foreign Affairs reports, "China is Now in a Prewar Tempo of Political and Military Preparations." China has one goal: take control of Taiwan, and an invasion could happen any day. I've identified 5 investments I believe are in immediate danger. But you can get out of them now - before it's too late.
Virios Therapeutics's Earnings Outlook
VIRI: Encouraging Results for IMC-2 in Long COVID…
CCL, S and LL are among pre market gainers
VIRI: Ready to Move IMC-1 Into Phase 3 Program…
10-Q: VIRIOS THERAPEUTICS, INC.
Recap: Virios Therapeutics Q1 Earnings
See More Headlines
Receive VIRI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Virios Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

VIRI Company Calendar

Last Earnings
8/10/2023
Today
9/20/2023
Next Earnings (Estimated)
11/13/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VIRI
Fax
N/A
Employees
4
Year Founded
N/A

Profitability

Net Income
$-12,250,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.88 per share

Miscellaneous

Free Float
17,245,000
Market Cap
$19.63 million
Optionable
Not Optionable
Beta
1.95
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Mr. Gregory  DuncanMr. Gregory Duncan (Age 58)
    Chairman & CEO
    Comp: $559.59k
  • Dr. William L. Pridgen M.D. (Age 62)
    Founder & Director
    Comp: $35k
  • Ms. Angela Walsh (Age 56)
    CFO, SVP of Fin., Corp. Sec. & Treasurer
    Comp: $281.28k
  • Dr. R. Michael Gendreau M.D. (Age 67)
    Ph.D., Chief Medical Officer
    Comp: $420.64k
  • Mr. Ralph D. Grosswald M.P.H. (Age 54)
    Sr. VP of Operations
  • Ms. Carol Duffy Ph.D.
    Chief Scientific Advisor













VIRI Stock - Frequently Asked Questions

How have VIRI shares performed in 2023?

Virios Therapeutics' stock was trading at $0.2360 on January 1st, 2023. Since then, VIRI shares have increased by 332.2% and is now trading at $1.02.
View the best growth stocks for 2023 here
.

Are investors shorting Virios Therapeutics?

Virios Therapeutics saw a decline in short interest in the month of August. As of August 31st, there was short interest totaling 465,100 shares, a decline of 17.9% from the August 15th total of 566,300 shares. Based on an average trading volume of 688,600 shares, the days-to-cover ratio is presently 0.7 days.
View Virios Therapeutics' Short Interest
.

When is Virios Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our VIRI earnings forecast
.

How were Virios Therapeutics' earnings last quarter?

Virios Therapeutics, Inc. (NASDAQ:VIRI) posted its earnings results on Thursday, August, 10th. The company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.07) by $0.01.

When did Virios Therapeutics IPO?

(VIRI) raised $30 million in an initial public offering (IPO) on Thursday, December 17th 2020. The company issued 3,000,000 shares at $9.00-$11.00 per share. ThinkEquity (a division of Fordham Financial Management) acted as the underwriter for the IPO.

What is Virios Therapeutics' stock symbol?

Virios Therapeutics trades on the NASDAQ under the ticker symbol "VIRI."

Who are Virios Therapeutics' major shareholders?

Virios Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Geode Capital Management LLC (0.80%), State Street Corp (0.29%), Citadel Advisors LLC (0.18%), McCollum Christoferson Group LLC (0.17%), Belvedere Trading LLC (0.10%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Angela Walsh, Gregory Scott Duncan, Richard James Whitley and William Pridgen.
View institutional ownership trends
.

How do I buy shares of Virios Therapeutics?

Shares of VIRI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Virios Therapeutics' stock price today?

One share of VIRI stock can currently be purchased for approximately $1.02.

How much money does Virios Therapeutics make?

Virios Therapeutics (NASDAQ:VIRI) has a market capitalization of $19.63 million. The company earns $-12,250,000.00 in net income (profit) each year or ($0.55) on an earnings per share basis.

How can I contact Virios Therapeutics?

The official website for the company is www.virios.com. The company can be reached via phone at 866-620-8655 or via email at ir@virios.com.

This page (NASDAQ:VIRI) was last updated on 9/21/2023 by MarketBeat.com Staff

My Account -